Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone Anne-Sophie Hamy, Raphaël Porcher, Caroline Cuvier, Sylvie Giacchetti, Marie-Hélène.

Slides:

Advertisements

Similar presentations

Cancer and fertility: strategies to preserve fertility

Advertisements

Attitudes and policies regarding access to fertility care and assisted reproductive technologies in Israel Daniel Sperling, Yael Simon Reproductive.

Vuong Thi Ngoc Lan, Nguyen Khanh Linh, Ho Manh Tuong, P. C

Fresh and cryopreserved ovary transplantation and resting follicle recruitment Sherman Silber, Jorge Pineda, Kathleen Lenahan, Michael DeRosa, Jeffrey.

FMR1 gene CGG repeat variation within the normal range is not predictive of ovarian response in IVF cycles Scott J. Morin, Ashley W. Tiegs, Jason M.

Norbert Gleicher, Andrea Weghofer, David H. Barad

Protective effect of resveratrol against oxidative damage to ovarian reserve in female Sprague–Dawley rats Pınar Özcan, Cem Fıçıcıoğlu, Özge Kızılkale.

Targeted anti-apoptosis activity for ovarian protection against chemotherapy-induced ovarian gonadotoxicity Shun-Jen Tan, Li-Jen Lee, Chii-Ruey Tzeng,

S.M. Nelson, A. La Marca Reproductive BioMedicine Online

External validation of nomogram for the decline in serum anti-Müllerian hormone in women: a population study of 15,834 infertility patients Scott M.

Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction Antonio La Marca, Giovanni D’Ippolito

Advanced glycation end product concentrations in follicular fluid of women undergoing IVF/ICSI with a GnRH agonist protocol Qi Yao, Yuanjiao Liang, Yong.

Intra-cycle fluctuations of anti-Müllerian hormone in normal women with a regular cycle: a re-analysis Annelies Overbeek, Frank J. Broekmans, Wouter.

Anti-Müllerian hormone for the assessment of ovarian response in GnRH-antagonist- treated oocyte donors Nikolaos P. Polyzos, Dominic Stoop, Christophe.

A. La Marca, G. Sighinolfi, S. Giulini, M. Traglia, C. Argento, C

In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation

Follicular-fluid anti-Mullerian hormone concentrations are predictive of assisted reproduction outcome in PCOS patients Recai Pabuccu, Cemil Kaya, Gamze.

Factors affecting embryo viability and uterine receptivity: insights from an analysis of the UK registry data Stephen A. Roberts, Mark Hann, Daniel R.

Gillian M. Lockwood Reproductive BioMedicine Online

Female gender pre-selection by maternal diet in combination with timing of sexual intercourse – a prospective study A.M. Noorlander, J.P.M. Geraedts,

Establishment and validation of a score to predict ovarian response to stimulation in IVF Clelia Chalumeau, Jessika Moreau, Nicolas Gatimel, Clementine.

Anti-Müllerian hormone as a predictor of pregnancy following IVF

Anti-Müllerian hormone as an independent predictor of twin versus singleton pregnancy in fresh cycles Reshef Tal, David B. Seifer, Moisey Khanimov, Eliana.

Sherman Silber Reproductive BioMedicine Online

Why are reproductive cancers more common in nulliparous women?

K. Gersak, A. Veble Reproductive BioMedicine Online

Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers Andrea.

Moniek van der Zanden, Annemiek W. Nap Reproductive BioMedicine Online

Utility of age-specific serum anti-Müllerian hormone concentrations

What’s on the mind of IVF consumers?

S Munné, E Fragouli, P Colls, MG Katz-Jaffe, WB Schoolcraft, D Wells

Ellen W. Freeman, Ph. D. , Clarisa R. Gracia, M. D. , Mary D

Sarah McCredie, William Ledger, Christos A. Venetis

Effect of N-acetyl-cysteine after ovarian drilling in clomiphene citrate-resistant PCOS women: a pilot study A. Nasr Reproductive BioMedicine Online

Fertility preservation consultation for women with cancer: are we helping patients make high-quality decisions? Jayeon Kim, Allison M. Deal, Ursula Balthazar,

Deleterious effect of tobacco on IVF outcome and ovarian reserve as reflected by serum anti mullerian hormone (AMH) P. Barriere, T. Freour, D. Masson,

Ovarian reserve determinations suggest new function of FMR1 (fragile X gene) in regulating ovarian ageing Norbert Gleicher, Andrea Weghofer, David H.

M. Dieterich, M. Bolz, T. Reimer, S. Costagliola, B. Gerber

Removal of unilateral endometriomas is associated with immediate and sustained reduction in ovarian reserve Bulent Urman, Ebru Alper, Kayhan Yakin, Ozgur.

Morphological systems of human embryo assessment and clinical evidence

Sequential use of letrozole and gonadotrophin in women with poor ovarian reserve: a randomized controlled trial Vivian Chi Yan Lee, Carina Chi Wai Chan,

Cassandra’s prophecy: medic or mother

Male age negatively influences clinical pregnancy rate in women younger than 40 years undergoing donor insemination cycles Su-Ann Koh, Katherine Sanders,

Dehydroepiandrostendione sulphate and prediction of live birth after IVF in young women with low anti-Müllerian hormone concentration Miro Šimun Alebić,

Mid-follicular LH supplementation in women aged 35–39 years undergoing ICSI cycles: a randomized controlled study R Matorras, B Prieto, A Exposito, R.

Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer Anne Perdrix, Mathilde Saint-Ghislain,

V Isachenko, E Isachenko, R Kreienberg, M Woriedh, JM Weiss

LH concentrations do not correlate with pregnancy in rFSH/GnRH antagonist cycles Kevin Doody, Paul Devroey, Keith Gordon, Han Witjes, Bernadette Mannaerts

Should we be promoting embryo transfer at blastocyst stage?

Stephen C. Collins, Esther Chan Reproductive BioMedicine Online

Pietro Gambadauro, Ramesan Navaratnarajah

Serum inhibin A concentration in women with polycystic ovarian syndrome and the correlation to ethnicity, androgens and insulin resistance Shimon Segal,

Does exogenous LH in ovarian stimulation improve assisted reproduction success? An appraisal of the literature Micah J. Hill, Gary Levy, Eric D. Levens

Jeff G. Wang, Nataki C. Douglas, Gary S. Nakhuda, Janet M

The Alpha Consensus Meeting on the professional status of the clinical embryologist: proceedings of an expert meeting Reproductive BioMedicine Online

A. La Marca, S. M. Nelson, G. Sighinolfi, M. Manno, E. Baraldi, L

Outcomes of immature oocytes collected from ovarian tissue for cryopreservation in adult and prepubertal patients Giovanna Fasano, Julie Dechène, Raffaella.

Is parental consanguinity associated with reduced ovarian reserve?

Nigel Pereira, Anna Voskuilen-Gonzalez, Kolbe Hancock, Jovana P

The impact of adenomyosis on the outcome of IVF–embryo transfer

Anti-Müllerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnancies Anne-Sophie Hamy, Raphaël.

Predictive value of ovarian reserve markers in smoking and non-smoking women undergoing IVF Thomas Freour, Lionel Dessolle, Miguel Jean, Damien Masson,

Ovarian reserve screening before contraception?

Cryobanking of human ovarian tissue: do women still want their tissue stored beyond 5 years? Kirsten Tryde Macklon, Erik Ernst, Anders Nyboe Andersen,

The significance of the number of CGG repeats and autoantibodies in premature ovarian failure Cem Fıçıcıoglu, Gazi Yildirim, Rukset Attar, Banu Kumbak,

Reproductive BioMedicine Online

John Yovich, James Stanger, Peter Hinchliffe

M. Franz, J. Ott, A. Watrelot, L. Küssel, H. Husslein

Fertility in cancer patients after cryopreservation of one ovary

Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era? Antonio La Marca, Martina Capuzzo Reproductive.

Presentation transcript:

Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone Anne-Sophie Hamy, Raphaël Porcher, Caroline Cuvier, Sylvie Giacchetti, Marie-Hélène Schlageter, Christiane Coussieu, Héloise Gronier, Jean-Paul Feugeas, Nadir Adoui, Jean-Marc Lacorte, Catherine Poirot, Mohamed Habdous, Marc Espié Reproductive BioMedicine Online Volume 29, Issue 5, Pages 573-580 (November 2014) DOI: 10.1016/j.rbmo.2014.07.008 Copyright © 2014 Reproductive Healthcare Ltd. Terms and Conditions

Figure 1 Baseline Anti-Müllerian hormone (AMH) grouped by age cohort and by menstrual status after chemotherapy; (A) baseline AMH concentrations in four age groups (<30 years, 30–34 years, 35–39 years and > 40 years); (B and C) baseline AMH concentrations in women with (white bars) or without (grey bars) chemotherapy-related amenorrhoea for (B) 6 months (n = 116, missing data: n = 18); and (C) 12 months (n = 96, missing data: n = 38) after starting chemotherapy; *, P = 0.002 compared with no amenorrhea. Reproductive BioMedicine Online 2014 29, 573-580DOI: (10.1016/j.rbmo.2014.07.008) Copyright © 2014 Reproductive Healthcare Ltd. Terms and Conditions

Figure 2 The black points represent baseline values measured before chemotherapy; the red points are values measured during chemotherapy, and the blue ones are values measured after chemotherapy. The dashed line represents the average increase after chemotherapy and the grey area is the 95% credibility interval. The horizontal grey line shows the limit of detection of Anti-Müllerian hormone. The shaded area represents the values of an Anti-Müllerian hormone below the 0.14 threshold. AMH = Anti-Müllerian hormone. Reproductive BioMedicine Online 2014 29, 573-580DOI: (10.1016/j.rbmo.2014.07.008) Copyright © 2014 Reproductive Healthcare Ltd. Terms and Conditions

Figure 3 Anti-Müllerian hormone (AMH) changes over time (log scale, slope per year), as a function of patient age. Reproductive BioMedicine Online 2014 29, 573-580DOI: (10.1016/j.rbmo.2014.07.008) Copyright © 2014 Reproductive Healthcare Ltd. Terms and Conditions